# Neo-adjuvant Abiraterone Prostate Study

> **NCT02160353** · PHASE2 · COMPLETED · sponsor: **Cancer Trials Ireland** · enrollment: 45 (actual)

## Conditions studied

- High Risk Localised Prostate Carcinoma

## Interventions

- **DRUG:** Abiraterone acetate, Prednisolone

## Key facts

- **NCT ID:** NCT02160353
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-09
- **Primary completion:** 2021-01-19
- **Final completion:** 2021-01-19
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02160353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02160353, "Neo-adjuvant Abiraterone Prostate Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02160353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*